Who is sponsoring NCT03925896?

NCT03925896 is sponsored by Sun Yat-sen University.

What drugs are being tested in NCT03925896?

Interventions in NCT03925896: LMP2 Antigen-specific TCR T cells.

What condition does NCT03925896 study?

NCT03925896 studies Nasopharyngeal Carcinoma.

Is NCT03925896 still recruiting?

NCT03925896 is currently status unknown. Last updated 12 September 2019.

Last reviewed 2019-09-12 · How we verify

NCT03925896

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase I Trial of LMP2 Antigen-specific TCR T-cell Therapy for Recurrent and Metastatic NPC Patients

Status unknown Phase 1 Last updated 12 September 2019

What this trial tests

Phase 1 trial testing LMP2 Antigen-specific TCR T cells in Nasopharyngeal Carcinoma in 27 participants. Status unknown.

Timeline

7 August 2019

Primary endpoint
1 August 2020

1 August 2022

Quick facts

Lead sponsor	Sun Yat-sen University
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	27
Start date	7 August 2019
Primary completion	1 August 2020
Estimated completion	1 August 2022
Sites	1 location across China

Drugs / interventions tested

LMP2 Antigen-specific TCR T cells — full drug profile →

Conditions studied

Nasopharyngeal Carcinoma — all drugs for Nasopharyngeal Carcinoma →

Sponsor

Sun Yat-sen University

Who can join

Adults 18 to 70, any sex, with Nasopharyngeal Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this study, a single-arm, open-labeled clinical trial will be performed to determine the safety and efficacy of EBV TCR-T cells in the treatment of recurrent/metastatic nasopharyngeal carcinoma with positive EBV infection in the Chinese population.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

TCR-engineered T cell therapy in solid tumors: State of the art and perspectives.
Baulu E, Gardet C, Chuvin N, Depil S. · · 2023 · cited 283× · PMID 36791198 · DOI 10.1126/sciadv.adf3700
Heterogeneity of the tumor immune microenvironment and its clinical relevance.
Jia Q, Wang A, Yuan Y, Zhu B, et al · · 2022 · cited 176× · PMID 35461288 · DOI 10.1186/s40164-022-00277-y
T-cell receptor-based therapy: an innovative therapeutic approach for solid tumors.
Tsimberidou AM, Van Morris K, Vo HH, Eck S, et al · · 2021 · cited 119× · PMID 34193217 · DOI 10.1186/s13045-021-01115-0
Immunotherapy for nasopharyngeal carcinoma: Current status and prospects (Review).
Huang H, Yao Y, Deng X, Huang Z, et al · · 2023 · cited 78× · PMID 37417358 · DOI 10.3892/ijo.2023.5545
Recurrent/Metastatic Nasopharyngeal Carcinoma Treatment from Present to Future: Where Are We and Where Are We Heading?
Juarez-Vignon Whaley JJ, Afkhami M, Onyshchenko M, Massarelli E, et al · · 2023 · cited 71× · PMID 37318724 · DOI 10.1007/s11864-023-01101-3
HNSCC: Tumour Antigens and Their Targeting by Immunotherapy.
von Witzleben A, Wang C, Laban S, Savelyeva N, et al · · 2020 · cited 70× · PMID 32942747 · DOI 10.3390/cells9092103
Immunotherapeutic approaches in EBV-associated nasopharyngeal carcinoma.
Li W, Duan X, Chen X, Zhan M, et al · · 2022 · cited 56× · PMID 36713430 · DOI 10.3389/fimmu.2022.1079515
T Cell Based Immunotherapy for Cancer: Approaches and Strategies.
Want MY, Bashir Z, Najar RA. · · 2023 · cited 44× · PMID 37112747 · DOI 10.3390/vaccines11040835

Verify or expand the search:

Other recruiting trials for Nasopharyngeal Carcinoma

Currently open trials in the same condition.

NCT06059261 — Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC. · Phase 2 · recruiting
NCT07328854 — 40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma · Phase 3 · recruiting
NCT06912711 — TN Induction and Adjuvant Therapy for Resectable Local Recurrent Nasopharyngeal Carcinoma · Phase 2 · recruiting
NCT07000643 — Phase III Non-Inferiority Trial of Proton Versus Photon Therapy for Nasopharyngeal Carcinoma · Phase 3 · recruiting
NCT06682442 — Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal Carcinoma · NA · recruiting

Other Sun Yat-sen University trials

Trials by the same sponsor.

NCT07255612 — Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negat · Phase 2 · not yet recruiting
NCT07371897 — Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial · Phase 3 · not yet recruiting
NCT07489703 — SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC · Phase 2 · not yet recruiting
NCT07528209 — Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer · Phase 3 · recruiting
NCT07522281 — Evaluation of an Undisturbed Embryo Culture System for Embryo Development in IVF/ICSI Cycles · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03925896 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sun Yat-sen University
Last refreshed: 12 September 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03925896.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing